Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16795113 | 1.00 | MEN1 (0.34) | MEN1KMT2AADRA2AADRA2BADRA2C | |
| SCHEMBL16797353 | 0.79 | — | — | |
| SCHEMBL18338825 | 0.79 | — | — | |
| SCHEMBL31600623 | 0.76 | ADRA2A (0.58) | MEN1KMT2AADRA2AADRA2BADRA2C | |
| SCHEMBL619591 | 0.76 | ADRA2A (0.58) | MEN1KMT2AADRA2AADRA2BADRA2C | |
| SCHEMBL619590 | 0.76 | ADRA2A (0.58) | MEN1KMT2AADRA2AADRA2BADRA2C | |
| SCHEMBL21572709 | 0.73 | PLAU (0.39) | PLAU | |
| SCHEMBL31200216 | 0.72 | PLAU (0.38) | PLAU | |
| SCHEMBL19761076 | 0.72 | PLAU (0.38) | PLAU | |
| SCHEMBL26664362 | 0.72 | PLAU (0.38) | PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080127-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | disclosed |
| US-9932342-B2 | Imidazopyrimidine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-04-03 | — | — | US | disclosed |
| US-20160297827-A1 | Imidazopyrimidine Derivatives As Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297827-A1 | Imidazopyrimidine Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | MEN1 4190/4885KMT2A 3421/4885ADRA2A 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.